SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences to launch generic Semaglutide under brand ‘SUNDAE’ in India

21 Mar 2026 Evaluate

Eris Lifesciences is all set to launch generic Semaglutide under the brand ‘SUNDAE’ in India on March 21, 2026. The company is introducing SUNDAE in multi-dose vial formats at highly accessible pricing starting at Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants. This launch significantly improves affordability, bringing effective GLP-1 therapy within reach for nearly 70% of India’s diabetes patient population. The company also plans to further enhance patient convenience and adoption with the introduction of a pen-device version in April priced at MRP of Rs 4,000, Rs 4,200 and Rs 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively. 

Semaglutide, a GLP-1 receptor agonist, has emerged as a transformative therapy for Type 2 diabetes and weight management, driven by strong outcomes in glycemic control and weight reduction. With India’s rapidly growing diabetic population and rising awareness of obesity, GLP-1 therapies present a significant growth opportunity.

Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.

Eris Lifesciences Share Price

1392.80 41.50 (3.07%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×